Unlearn Digital Twins
Simulate likely outcomes for individual clinical trial participants.
Unlearn AI Funding History
Unlearn AI generates AI-based digital twins of clinical trial participants to reduce control-arm sizes.
Company Overview
Unlearn AI
Founded 2017 · San Francisco, California, US
Official WebsiteUnlearn AI Funding Timeline
Series C
US$50 million
The company planned to expand the engineering and research behind digital twins used to model clinical-trial participants.
Led by Altimeter Capital. Participation included Insight Partners.
Source · dcvc.com ↗Series B
US$50 million
Unlearn said it would use the financing to expand the use of digital twins in randomized clinical trials.
Led by Insight Partners.
Source · businesswire.com ↗Series A
US$12 million
Unlearn was developing digital twins to supplement control groups in clinical trials with simulated patient data.
Led by 8VC. Participation included DCVC, DCVC Bio.
Source · biospace.com ↗Pre-Seed
US$0.7 million
Unlearn’s founder said the company raised its pre-seed from DCVC based on a thesis about generative models, before it focused on clinical trials.
Led by DCVC.
Source · dcvc.com ↗
Unlearn AI Founding Team
Physicists Charles Fisher, Aaron Smith, and Jon Walsh founded Unlearn AI to bring computational modeling to clinical research. Fisher led the company as CEO.
Unlearn AI Products
Unlearn AI Company Development
Digital Twins in Trial Design
Unlearn developed its approach around using participant data to predict likely outcomes over time. Those predictions can be used when designing a randomized trial, with the aim of reducing the number of people needed in the control arm.
Unlearn AI Competitive Landscape
Trial Design Versus Patient Recruitment
Recruitment platforms help find enough eligible participants for a planned trial. Unlearn works on the design itself: if the statistical method supports it, the study may require fewer participants in the control arm.
